-

Blade Therapeutics Mourns the Passing of General Counsel and Secretary Alan C. Mendelson

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (Blade) today announced with profound sadness the unexpected passing of company General Counsel and Secretary Alan C. Mendelson on October 8, 2021, in San Francisco.

Wendye Robbins, M.D., president and CEO of Blade, said, “I am shocked and saddened by my dear friend’s sudden passing. Alan had an immeasurable impact on our industry and touched the lives of so many people. On behalf of Blade’s Board of Directors, management team and employees, we extend our deepest sympathies to Alan’s family.”

Mr. Mendelson joined Blade as General Counsel and Secretary in February 2021. During more than 47 years of private practice, Mr. Mendelson focused on representing emerging and public growth companies, primarily in the life sciences industry. He served as the Global Co-Chair of the Life Sciences Industry Group for the Silicon Valley office of Latham & Watkins LLP, a major global law firm where he retired as senior partner after a 20-year career with the firm. Mr. Mendelson served as the incorporator of Amgen Inc. (NASDAQ: AMGN) in April 1980 and played a leading role in all of Amgen’s major transactions during the first 10 years of its existence.

Mr. Mendelson served as a long-standing member of the Board of Trustees of the University of California (UC) Berkeley Foundation and as a member of the Board of Advisors for the UC Berkeley College of Chemistry, a member of the Board of the UC Berkeley Library and a member of the Chancellor’s External Affairs Committee. He was also a member of the UC Innovation Council, established by UC to advise on technology and entrepreneurship initiatives for the UC system. Mr. Mendelson served on the Board of Trustees of The Buck Institute for Research on Aging. He also served on the board of directors of several companies.

The Legal 500, an industry publishing firm, has ranked Mr. Mendelson among just four individuals receiving a star in its Hall of Fame for legal professionals serving the life sciences sector. Mr. Mendelson was the first service provider to receive the Life Sciences Leadership Award at the BayBio Pantheon and was repeatedly recognized as one of the 100 most influential lawyers in the United States by the National Law Journal.

Blade Therapeutics

Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases that impact millions of people worldwide. Visit www.blademed.com and LinkedIn for more information.

Contacts

Media Relations – Michael Blash
mblash@blademed.com
+1-650-453-0632

Investor Relations – Krishna Gorti, M.D.
kgorti@blademed.com
+1-650-797-0314

Blade Therapeutics, Inc.

Details
Headquarters: South San Francisco, California
CEO: Wendye Robbins
Employees: 25
Organization: PRI

Release Summary
Blade Therapeutics mourns the passing of General Counsel and Secretary Alan C. Mendelson
Release Versions

Contacts

Media Relations – Michael Blash
mblash@blademed.com
+1-650-453-0632

Investor Relations – Krishna Gorti, M.D.
kgorti@blademed.com
+1-650-797-0314

More News From Blade Therapeutics, Inc.

Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022

SAN FRANCISCO--(BUSINESS WIRE)--Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the presentation of positive data from Phase 1 and preclinical studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. The data were featured in a poster (abstract #PA459) presented today at the European...

Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

SAN FRANCISCO--(BUSINESS WIRE)--Blade Therapeutics to participate in “Drug Development in Pulmonary Medicine” panel discussion on August 9 at the 2022 BTIG Biotechnology Conference...

Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics announces new data from preclinical studies that highlight differentiating characteristics of cudetaxestat in poster at ATS 2022....
Back to Newsroom